Israel-based pharmaceutical firm Teva Pharmaceutical will acquire the remaining 50% stake of its Teva-Kowa Pharma joint venture, turning the venture into a wholly owned subsidiary.
Teva originally started the joint venture with Japanese firm Kowa in 2008 and will purchase the remaining stake for approximately $150m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The move comes after generic manufacturer converted Taiyo Pharmaceuticals into a 100% subsidiary in July 2011 and will make Teva Japan’s largest generic drug company.
As a result of the acquisition, Teva has brought forward its 2015 sales target of 100bn yen ($1.3bn).
